Medivizor

Title of notification

Here comes the notification
X
 
icon
icon
breast cancer | Research | Lifestyle | 10 pages | source: Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer | Added Jan 12, 2020

Mindfulness-based interventions in cancer patients and survivors

This review aimed to summarize available data about the effectiveness of mindfulness-based interventions for cancer-related symptoms in cancer patients and survivors.  

This review concluded that mindfulness-based interventions can have a beneficial effect as an adjuvant therapy in these patients.  

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Arthritis Research & Therapy | Added Dec 31, 2019

Upadacitinib – an update on patient-reported outcomes

This study investigated patient-reported outcomes (PROs) in patients taking upadacitinib (Rinvoq) to treat rheumatoid arthritis (RA). They found that this treatment improved the quality of life (QoL) in these patients.

icon
breast cancer | Research | 10 pages | source: Archives of Gynecology and Obstetrics | Added Dec 30, 2019

Chemotherapy in patients with hormone receptor positive, node positive invasive breast cancer

This study wanted to find out how well chemotherapy for invasive breast cancer works, especially in those over 70 years old. The study found that most patients benefit from chemotherapy, however, those aged over 70 benefited less of this treatment than those aged under 70.

icon
icon
rheumatoid arthritis | Research | Lifestyle | 10 pages | source: Nutrients | Added Dec 29, 2019

What are the benefits of dietary fiber in patients with rheumatoid arthritis?

This study investigated the effect of dietary fiber supplementation (DFS) in patients with rheumatoid arthritis (RA). They found that DFS may improve RA symptoms.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Clinical drug investigation | Added Nov 29, 2019

Comparing the safety and effectiveness of peficitinib doses in patients with rheumatoid arthritis

This study investigated the safety and effectiveness of different doses of peficitinib (Smyraf; PFC) in treating rheumatoid arthritis (RA). They found that PFC doses of 50 mg or higher were the most effective in these patients.

icon
rheumatoid arthritis | Research | 10 pages | source: Arthritis Care & Research | Added Sep 27, 2019

Is there a greater risk of serious infection with tumor necrosis factor inhibitors for rheumatoid arthritis?

This study investigated the risk of serious infections with tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA).

They found no difference in serious infection risk with TNFi treatment compared to triple therapy.

icon
breast cancer | Research | 10 pages | source: Lancet (London, England) | Added Sep 16, 2019

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. They found that cancer survivors have a higher risk of CVD.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Lancet (London, England) | Added Sep 10, 2019

Upadacitinib improves clinical outcomes of patients with rheumatoid arthritis

This study investigated the safety and effectiveness of upadacitinib (Rinvoq) in patients with rheumatoid arthritis (RA) who progressed after methotrexate (Otrexup). Researchers suggested that upadacitinib improved clinical and functional outcomes in these patients.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Annals of the rheumatic diseases | Added Sep 08, 2019

Peficitinib – a drug to treat unresponsive rheumatoid arthritis?

This study investigated the safety and effectiveness of peficitinib (Smyraf) in patients with unresponsive rheumatoid arthritis (RA). 

They found that this treatment reduced RA symptoms and was well tolerated in these patients.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Journal of the American Medical Association (JAMA) | Added Aug 28, 2019

How effective is filgotinib in the treatment of unresponsive rheumatoid arthritis?

This study investigated the effectiveness of filgotinib (FGB) in patients with unresponsive rheumatoid arthritis (RA).

They found that FGB improves RA management at 12 weeks. 

View

Conditions

Category

  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon

Was this helpful?